ArticleNeurology and therapy2025

Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis.

Stephen L Hauser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.